Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CHAT | P28329 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10628442 | 0.83 | HDAC3 (0.42) | MAOBRELANPC1RAB9ACHAT | |
| SCHEMBL12903021 | 0.80 | NFE2L2 (0.45) | RELANPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL10628647 | 0.79 | HDAC3 (0.51) | MAOBRELANPC1RAB9ATDP1 | |
| SCHEMBL1506756 | 0.78 | EGFR (0.54) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11281860 | 0.77 | MAOB (0.44) | MAOBNPC1RAB9ATRPA1ALDH1A1 | |
| SCHEMBL10628483 | 0.77 | EGFR (0.56) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27702754 | 0.77 | CHAT (0.41) | MAOBRELANPC1RAB9ACHAT | |
| SCHEMBL10623848 | 0.77 | EGFR (0.56) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27636014 | 0.77 | EGFR (0.56) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12903026 | 0.77 | RELA (0.53) | RELAL3MBTL1GLAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104870482-B | Molecularly imprinted polymer and its purposes as anti-dandruff agent | 莱雅公司 | 2017-10-24 | — | — | CN | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| EP-2333887-B1 | METHOD FOR PRODUCING ANION EXCHANGE MEMBRANE FOR SOLID POLYMER ELECTROLYTE-TYPE FUEL CELL | TOKUYAMA CORP (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| CN-104880908-A | Photosensitive resin composition | SUMITOMO CHEMICAL CO | 2015-09-02 | — | — | CN | disclosed |
| US-8399154-B2 | Method for producing an anion-exchange membrane for a solid polymer electrolyte type fuel cell | TOKUYAMA CORPORATION (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110207028-A1 | Method for Producing an Anion-Exchange Membrane for a Solid Polymer Electrolyte Type Fuel Cell | TOKUYAMA CORPORATION (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2333887-A1 | METHOD FOR PRODUCING ANION EXCHANGE MEMBRANE FOR SOLID POLYMER ELECTROLYTE-TYPE FUEL CELL | Tokuyama Corporation (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20110104590-A1 | Method for Producing Ion Conductivity Providing Agent for Catalyst Electrode Layer in Anion-Exchange Membrane Type Fuel Cell | TOKUYAMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| EP-1119660-A1 | CELLULOSIC SUPPORT TREATMENT | MORGAN ADHESIVES COMPANY (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001004418-A1 | CELLULOSIC SUPPORT TREATMENT | MORGAN ADHESIVES COMPANY (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5506275-A | RESISTANCE TO ABRASION AND CRACKING ON FLEX | BASF CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5180799-A | Organolithium-Organoaluminum Catalyst | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-19 | — | — | US | disclosed |
| EP-0434316-A1 | Processes | ZENECA LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4734351-A | DISPERSION OF POLYMER | FUJI PHOTO FILM CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| CN-86103603-A | The preparation method of the derivative of benzothiazine dioxide | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0091039-B1 | ANTI-FOULING AGENT | Nitto Kasei Co., Ltd. (JP) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | MAOB 3229/4885RELA 2329/4885NPC1 2512/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | MAOB 2493/4885RELA 1978/4885NPC1 2248/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | MAOB 3994/4885RELA 2888/4885NPC1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.